{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.5","upperLimit":"3.2","value":"2.6"},{"groupId":"OG001","lowerLimit":"1.1","upperLimit":"3.2","value":"1.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"24"}],"units":"Participants"}],"description":"The distribution of PFS will be estimated using the method of Kaplan-Meier. The comparison of progression-free survival between two treatment arms will be based on the log-rank test.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive nivolumab IV over 30 minutes every 2 weeks for 4 months and every 4 weeks for a total of up to 2 years in the absence of disease progression or unacceptable toxicity. Patients may cross over to Group II at the time of disease progression.","id":"OG000","title":"Group I (Nivolumab)"},{"description":"Patients receive varlilumab IV over 90 minutes every 4 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients also receive nivolumab IV over 30 minutes every 2 weeks for 4 months and every 4 weeks for a total of up to 2 years in the absence of disease progression or unacceptable toxicity.","id":"OG001","title":"Group II (Varlilumab, Nivolumab)"}],"paramType":"MEAN","populationDescription":"All eligible and treated patients that had a disease evaluation.","reportingStatus":"POSTED","timeFrame":"37 months","title":"Progression Free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"Months"}